Additional risk factors in our patient included decreased intake of carbohydrates, reduction of insulin doses, possible metabolic decompensation of diabetes and increased insulin resistance associated with intercurrent illness
GLP-1 RAs: FDA Indications as of February 2026 *Combination GLP-1 RA and glucose-dependent insulinotropic polypeptide RA
Regular healthcare consultations, careful monitoring, and adherence to professional guidance help patients maximize benefits while minimizing risks
These medications mimic the GLP-1 hormone to support weight loss and blood sugar control
Luthione is medically indicated for the prevention of neurotoxicity resulting from cisplatin-based or similar chemotherapeutic regimens
Rogozhin, Institute of Bioorganic Chemistry (RAS), Russia Luminita Marutescu, University of Bucharest, Romania Updates Copyright 2025 Sceglovs, Skadins, Chitto, Kroica and Salma-Ancane